1. Home
  2. AGIO vs STRA Comparison

AGIO vs STRA Comparison

Compare AGIO & STRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$32.48

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Logo Strategic Education Inc.

STRA

Strategic Education Inc.

N/A

Current Price

$78.79

Market Cap

1.9B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
AGIO
STRA
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
AGIO
STRA
Price
$32.48
$78.79
Analyst Decision
Buy
Buy
Analyst Count
10
3
Target Price
$46.25
★ $98.33
AVG Volume (30 Days)
★ 686.1K
199.7K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
★ 3.09%
EPS Growth
N/A
★ 15.85
EPS
N/A
★ 3.19
Revenue
$43,011,000.00
★ $997,137,000.00
Revenue This Year
$237.78
$2.51
Revenue Next Year
$92.30
$2.95
P/E Ratio
★ N/A
$23.68
Revenue Growth
N/A
★ 57.23
52 Week Low
$22.24
$69.70
52 Week High
$46.00
$89.73

Technical Indicators

Market Signals
Indicator
AGIO
STRA
Relative Strength Index (RSI) 48.96 47.72
Support Level $32.17 $77.84
Resistance Level $35.77 $85.36
Average True Range (ATR) 1.18 2.55
MACD -0.00 -0.21
Stochastic Oscillator 51.25 40.79

Price Performance

Historical Comparison
AGIO
STRA

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About STRA Strategic Education Inc.

Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.

Share on Social Networks: